Adam Ivey

3.7k total citations
29 papers, 764 citations indexed

About

Adam Ivey is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Adam Ivey has authored 29 papers receiving a total of 764 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 16 papers in Molecular Biology and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Adam Ivey's work include Acute Myeloid Leukemia Research (26 papers), Acute Lymphoblastic Leukemia research (8 papers) and Histone Deacetylase Inhibitors Research (8 papers). Adam Ivey is often cited by papers focused on Acute Myeloid Leukemia Research (26 papers), Acute Lymphoblastic Leukemia research (8 papers) and Histone Deacetylase Inhibitors Research (8 papers). Adam Ivey collaborates with scholars based in Australia, United Kingdom and New Zealand. Adam Ivey's co-authors include David Grimwade, Brian J.P. Huntly, Andrew H. Wei, Ing Soo Tiong, Chun Yew Fong, Sun Loo, Chong Chyn Chua, Shaun Fleming, Andrew W. Roberts and Jessica M. Salmon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.

In The Last Decade

Adam Ivey

27 papers receiving 758 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adam Ivey Australia	11	618	367	170	162	95	29	764
Tiejun Qin China	15	471 0.8×	232 0.6×	323 1.9×	42 0.3×	60 0.6×	88	599
Jutta Bradtke Germany	13	375 0.6×	235 0.6×	99 0.6×	301 1.9×	107 1.1×	20	623
A. R. Zander Germany	8	332 0.5×	102 0.3×	176 1.0×	102 0.6×	137 1.4×	16	555
Albert Pérez-Ladaga Spain	3	362 0.6×	214 0.6×	148 0.9×	39 0.2×	43 0.5×	4	494
Xiao‐Su Zhao China	17	632 1.0×	193 0.5×	86 0.5×	227 1.4×	143 1.5×	45	852
Jo-Anne Vergilio United States	7	198 0.3×	147 0.4×	166 1.0×	43 0.3×	64 0.7×	8	457
Ryan J. Mattison United States	12	273 0.4×	238 0.6×	159 0.9×	71 0.4×	111 1.2×	58	518
Lisa Eidenschink Brodersen United States	12	470 0.8×	195 0.5×	146 0.9×	133 0.8×	106 1.1×	43	597
S Nakazawa Japan	10	204 0.3×	131 0.4×	48 0.3×	135 0.8×	84 0.9×	24	387
Santiago Gardella Spain	10	266 0.4×	194 0.5×	176 1.0×	86 0.5×	225 2.4×	22	518

Countries citing papers authored by Adam Ivey

Since Specialization

Citations

This map shows the geographic impact of Adam Ivey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Ivey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Ivey more than expected).

Fields of papers citing papers by Adam Ivey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Ivey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Ivey. The network helps show where Adam Ivey may publish in the future.

Co-authorship network of co-authors of Adam Ivey

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Ivey. A scholar is included among the top collaborators of Adam Ivey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Ivey. Adam Ivey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chua, Chong Chyn, Sun Loo, Chun Yew Fong, et al.. (2025). Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT). Blood Advances. 9(8). 1827–1835. 4 indexed citations

Tiong, Ing Soo, Devendra Hiwase, Ashish Bajel, et al.. (2024). Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). Journal of Clinical Oncology. 42(18). 2161–2173. 18 indexed citations

Othman, Jad, Nicola Potter, Adam Ivey, et al.. (2024). Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 143(19). 1931–1936. 33 indexed citations

Loo, Sun, Nicola Potter, Adam Ivey, et al.. (2024). Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia. Blood. 144(24). 2554–2557. 4 indexed citations

Fleming, Shaun, Adam Ivey, Andrew Spencer, et al.. (2023). Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome. Transplantation and Cellular Therapy. 29(7). 454.e1–454.e8. 3 indexed citations

Loo, Sun, Richard Dillon, Adam Ivey, et al.. (2022). Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 140(22). 2407–2411. 42 indexed citations

Tiong, Ing Soo, Devendra Hiwase, Ashish Bajel, et al.. (2022). A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia. Blood. 140(Supplement 1). 1453–1455. 4 indexed citations

Tiong, Ing Soo, Adam Ivey, Katherine Fielding, Chun Yew Fong, & Andrew H. Wei. (2022). Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes. Blood. 140(Supplement 1). 6258–6259.

Tiong, Ing Soo, Sun Loo, Devendra Hiwase, et al.. (2021). A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1261–1261. 2 indexed citations

10.

Tiong, Ing Soo, Richard Dillon, Adam Ivey, et al.. (2020). The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML). Blood. 136(Supplement 1). 25–27. 3 indexed citations

11.

Chua, Chong Chyn, Andrew W. Roberts, John Reynolds, et al.. (2020). Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. Journal of Clinical Oncology. 38(30). 3506–3517. 117 indexed citations

12.

Tiong, Ing Soo, Richard Dillon, Adam Ivey, et al.. (2020). Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia. British Journal of Haematology. 192(6). 1026–1030. 64 indexed citations

13.

Tiong, Ing Soo, Richard Dillon, Adam Ivey, et al.. (2019). Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 2648–2648.

14.

Salmon, Jessica M., Giovanna Pomilio, Donia M. Moujalled, et al.. (2018). Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity In AML. Experimental Hematology. 64. S99–S100. 2 indexed citations

15.

Salmon, Jessica M., Giovanna Pomilio, Donia M. Moujalled, et al.. (2018). Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML. Blood. 132(Supplement 1). 1426–1426. 3 indexed citations

16.

Grey, William, Adam Ivey, Thomas A. Milne, et al.. (2017). The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1865(1). 105–116. 10 indexed citations

17.

Grimwade, David, Adam Ivey, & Brian J.P. Huntly. (2015). Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 127(1). 29–41. 292 indexed citations

18.

Taylor, Gordon, et al.. (2013). Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot–Leyden crystals. International Journal of Hematology. 98(3). 267–268. 8 indexed citations

19.

Uttenthal, Benjamin J., Adam Ivey, Charles Craddock, et al.. (2013). Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short‐lived WT1‐specific immune responses. British Journal of Haematology. 164(3). 366–375. 48 indexed citations

20.

Burr, Jamie F., Shannon S. D. Bredin, Aaron A. Phillips, et al.. (2012). Systemic Arterial Compliance Following Ultra-Marathon. International Journal of Sports Medicine. 33(3). 224–229. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact